Vijaya Diagnostic Centre profit and loss

Latest FY26

Revenue: ₹814cr+19.5% on FY25
EBITDA: ₹337cr+23.3% on FY25
Net profit: ₹173cr+20.3% on FY25
EPS: ₹16.81+20.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	857	814	681	548	459	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	22.3	20.8	18.3	20.8	14.2
	879	835	700	569	473
	98.9	94.7	84.8	65.4	58.9
	137	131	112	90.2	78.5
	36.7	33.2	26.7	24.0	20.9
	96.1	91.8	70.6	57.0	61.7
	260	252	211	171	140
	628	602	506	408	360
	362	337	273	221	182
	266	245	203	164	120
Profit
	251	233	194	161	114
	0.0	0.0	−1.0	−2.1	0.0
	251	233	193	159	114
	55.7	50.7	41.2	33.2	27.8
	8.3	9.0	8.2	5.8	0.5
	63.9	59.7	49.4	39.0	28.3
	187	173	144	120	85.2
	187	173	144	120	85.2
	0.9	0.7	0.0	−0.1	0.2
	188	174	144	120	85.4
	187	173	143	119	84.6
	0.0	0.0	0.7	0.8	0.6
Per share
	₹18.23	₹16.81	₹13.95	₹11.62	₹8.29
	₹18.19	₹16.79	₹13.92	₹11.59	₹8.26
Other comprehensive income — detail
	0.9	0.7	0.0	—	—
	1.2	0.9	0.0	−0.1	0.3
	0.3	0.2	0.0	—	—
	—	—	—	−0.0	0.1
	188	174	143	119	84.8
	0.0	0.0	0.7	0.8	0.6
Per share — as-filed variants
	₹18.23	₹16.81	₹13.95	₹11.62	₹8.29
	₹18.19	₹16.79	₹13.92	₹11.59	₹8.26
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	758	720	597	482	400
	88.5%	88.4%	87.6%	88.1%	87.2%
Adjusted (ex-exceptional items) — derived
	251	233	194	161	114
	0.0	0.0	−1.0	−2.1	0.0
	187	173	145	121	85.2
	₹18.23	₹16.81	₹14.02	₹11.77	₹8.29

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIJAYA₹1,464.20

Vijaya Diagnostic Centre Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTHYROCARE METROPOLIS LALPATHLAB RAINBOW POLYMED PFIZER ONESOURCE KIMSMcap ₹15,066 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	459.2	547.8	681.4	814.2	857.1
Other Income	14.2	20.8	18.3	20.8	22.3
Total Income	473.4	568.6	699.7	835.0	879.4
Expenses
+ Cost of Materials Consumed	58.9	65.4	84.8	94.7	98.9
+ Employee Benefit Expense	78.5	90.2	112.2	130.7	136.6
+ Finance Costs	20.9	24.0	26.7	33.2	36.7
+ Depreciation & Amortisation	61.7	57.0	70.6	91.8	96.1
+ Other Expenses	139.8	171.2	211.3	251.8	259.7
Total Expenses	359.9	407.9	505.5	602.3	628.0
EBITDA	182.0	220.9	273.2	336.9	361.9
EBIT	120.3	163.9	202.6	245.1	265.9
Profit
PBT before Exceptional Items	113.5	160.7	194.2	232.7	251.4
+ Exceptional Items	0.0	-2.1	-1.0	0.0	0.0
Pretax Income	113.5	158.7	193.2	232.7	251.4
+ Current Tax	27.8	33.2	41.2	50.7	55.7
+ Deferred Tax	0.5	5.8	8.2	9.0	8.3
Tax Expense	28.3	39.0	49.4	59.7	63.9
Net Income	85.2	119.6	143.8	173.0	187.5
+ Net Income — Continuing Ops	85.2	119.6	143.8	173.0	187.5
+ Other Comprehensive Income	0.2	-0.1	0.0	0.7	0.9
Total Comprehensive Income	85.4	119.5	143.8	173.6	188.4
Net Income to Common	84.6	118.8	143.1	173.0	187.5
Minority Interest	0.6	0.8	0.7	0.0	0.0
Per Share
Basic EPS	8.29	11.62	13.95	16.81	18.23
Diluted EPS	8.26	11.59	13.92	16.79	18.19
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.0	0.7	0.9
+ Items NOT to be Reclassified to P&L	0.3	-0.1	0.0	0.9	1.2
+ Tax on Items NOT to be Reclassified	—	—	0.0	0.2	0.3
+ Tax on Items NOT to be Reclassified — alt tag	0.1	-0.0	—	—	—
Comprehensive Income — Owners of Parent	84.8	118.7	143.1	173.6	188.4
Comprehensive Income — Non-controlling Interests	0.6	0.8	0.7	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.29	11.62	13.95	16.81	18.23
Diluted EPS — Continuing Operations	8.26	11.59	13.92	16.79	18.19
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	400.3	482.4	596.6	719.5	758.3
Gross Margin %	87.18	88.05	87.56	88.37	88.47
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	113.5	160.7	194.2	232.7	251.4
− Exceptional Items (reconciliation)	0.0	-2.1	-1.0	0.0	0.0
Net Income Adj (tax-effected)	85.2	121.2	144.6	173.0	187.5
EPS Adj	8.29	11.77	14.02	16.81	18.23
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	10.2	10.2	10.3	10.3	10.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.